Gene therapy in the neuroendocrine system

Area of Science:

• Neuroendocrinology
• Gene Therapy
• Animal Models

Background:

• Neuroendocrine diseases involve complex hormonal regulation.
• Gene therapy offers a potential therapeutic avenue for these conditions.
• Existing animal models exhibit specific neuroendocrine dysfunctions.

Purpose of the Study:

• To evaluate the efficacy of experimental gene therapy in animal models of neuroendocrine diseases.
• To investigate the potential of viral vectors for restoring normal function in affected hypothalamic and pituitary regions.
• To assess gene therapy's impact on conditions like diabetes insipidus, obesity, and pituitary tumors.

Main Methods:

• Stereotactic injection of viral vectors into specific hypothalamic and pituitary regions in rat and mouse models.
• Utilized vectors expressing arginine vasopressin (AVP), leptin receptor b, proopiomelanocortin, insulin-like growth factor I, and retinoblastoma (Rb) gene cDNA.
• Employed adenoviral vectors for gene delivery in most experimental setups.

Main Results:

• Successfully restored arginine vasopressin in Brattleboro rats with diabetes insipidus.
• Corrected obesity, hyperphagia, and hyperinsulinemia in Koletsky and Zucker rats via leptin receptor gene therapy.
• Reversed chronic hyperprolactinemia and restored dopaminergic neuron numbers in aging rats using insulin-like growth factor I.
• Reduced spontaneous pituitary tumors in Rb gene mutant mice and experimental prolactinomas in rats.

Conclusions:

• Experimental gene therapy is a viable strategy for treating various neuroendocrine diseases in animal models.
• Viral vector-mediated gene delivery effectively targets relevant hypothalamic and pituitary pathways.
• These findings support further development of gene therapy for human neuroendocrine disorders.